吸入沙美特罗/酸氟替卡松对COPD患者血浆MMP-9及其TIMP-1水平的影响及疗效观察
The Effects of Inhaled Fluticasone Propionate on Plasma MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease and Observation of Therapeutic Efficacy
吉珉 1秦超1
作者信息
- 1. 浙江省宁海第一医院呼吸科,315600
- 折叠
摘要
目的:探讨吸入沙美特罗/酸氟替卡松对慢性阻塞性肺疾病(COPD)患者血浆基质金属蛋白酶-9(MMP-9)及其抑制剂-1(TIMP-1)的影响及疗效观察.方法:将74例COPD患者随机分为观察组和对照组.两组患者均予以低流量吸氧、抗感染、止咳化痰及解痉平喘等对症支持治疗.观察组在此基础上加用沙美特罗/酸氟替卡松吸入治疗,连用2周.结果:治疗2周后,两组患者血浆MMP-9水平均明显下降,血浆TIMP-1水平明显上升(P<0.05或P<0.01),且观察组上升或下降的幅度更明显(P<0.05);两组患者FEV1、FEV1/FVC和PEF均明显改善(P<0.05或P<0.01),且观察组改善的幅度较对照组更明显(P<0.05);观察组临床总有效率明显高于对照组(χ2 =5.23,P<0.05),治疗期间无严重药物不良反应.结论:沙美特罗/丙酸氟替卡松吸入治疗COPD安全有效,能明显改善肺功能,作用机制与其能调节血浆MMP-9和TIMP-1水平密切相关.
Abstract
Objective To investigate the effects of inhaled flulieasone ptopionate( FP) on plasma MMP-9 and TIMP-1 in patients with COPD and its therapeutic efficacy. Methods 72 patients with COPD were divided into observation group and control group. Control group patients were received the treatment of oxygen, antibiotics, drugs for relieving cough, sputum and asthma, and other symptomatic and supportive treatment. The observation group received an additional treatment of inhaled FP per day for 2 weeks. Results Plasma MMP-9 level decreased significantly and TIMP-1 level increased markedly in both two groups after 2 weeks' therapy (P <0.05 orP<0.01). But the change was more prominent in the observation group(P<0.05). Both two groups showed significant changes in the pulmonary function(FEV1, FEV1/FVC and PEF) in both two groups after 2 weeks' therapy(P<0.05 or P<0.01) , but the observation group improved more remarkably than the control group (P <0.05). The clinical total effective rate of observation group was more distinctly than that in the control group (X2 = 5.23, P <0.05). There were no significant serious adverse drug reactions in the both groups during treatment. Conclusion The treatment of COPD with inhaled FP provides good efficacy and safety, could improve pulmonary function, the mechanism may be closed related to regulating on the expressions of plasma MMP-9 and TIMP-1.
关键词
慢性阻塞性肺疾病/沙美特罗/酸氟替卡松/肺功能/血浆质金属蛋白酶-9/基质金属蛋白酶抑制剂-1Key words
chronic obstructive pulmonary disease(COPD)/fluticasone propionate/pulmnary function/MMP-9/TIMP-1引用本文复制引用
出版年
2013
NETL
NSTL
维普
万方数据